


# Reference Data

(Consolidated Financial Results for Q2 FY2011)



**Daiichi-Sankyo**

October 31, 2011

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

# MEMO

(This page is intentionally left blank)

# Contents

1.	Consolidated Income Statement	P1
2.	Currency Rate	P1
3.	Segment Information	P2
4.	Sales by Business Units	P3
5.	Sales of Global Products	P6
6.	Number of Employees	P7
7.	Management / Financial Indicators	P8
8.	Capital Expenditure and Depreciation Expenses	P8
9.	Consolidated Balance Sheets	P9
10.	Consolidated Statements of Cash Flow	P11
11.	R&D Pipeline	P13

## Supplemental Information

Historical Data

Summary of Product Outlines

## 1. Summary of Consolidated Income Statement

JPY Bn	Q1			Q2			Q3			Q4			Q2 YTD					FY2011				
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to forecast	to sales	Forecast	from Jul	YoY	YoY	
<b>Net sales</b>	<b>100%</b>	<b>231.7</b>	<b>-9.7%</b>	<b>100%</b>	<b>224.4</b>	<b>-7.5%</b>							<b>100%</b>	<b>456.0</b>	<b>-42.8</b>	<b>-8.6%</b>	<b>49%</b>	<b>100%</b>	<b>930.0</b>	<b>-40.0</b>	<b>-37.4</b>	<b>-3.9%</b>
Cost of sales	26%	59.9	-6.5%	31%	69.0	-7.4%							28%	128.9	-9.6	-7.0%	49%	28%	265.0	-25.0	-16.7	-5.9%
Gross Profit	74%	171.8	-10.7%	69%	155.4	-7.5%							72%	327.2	-33.2	-9.2%	49%	72%	665.0	-15.0	-20.7	-3.0%
SG&A expenses	55%	128.3	-2.3%	61%	136.7	-1.6%							58%	265.0	-5.3	-2.0%	47%	61%	565.0	-25.0	1.5	+0.3%
R&D expenses	18%	41.0	-5.9%	19%	43.0	-5.8%							18%	84.1	-5.2	-5.9%	44%	20%	190.0	-10.0	-4.3	-2.2%
Other expenses	38%	87.3	-0.5%	42%	93.7	+0.4%							40%	180.9	-0.1	-0.0%	48%	40%	375.0	-15.0	5.8	+1.6%
<b>Operating Income</b>	<b>19%</b>	<b>43.5</b>	<b>-28.8%</b>	<b>8%</b>	<b>18.7</b>	<b>-35.6%</b>							<b>14%</b>	<b>62.2</b>	<b>-27.9</b>	<b>-31.0%</b>	<b>62%</b>	<b>11%</b>	<b>100.0</b>	<b>10.0</b>	<b>-22.1</b>	<b>-18.1%</b>
Non-operating income / expenses		1.4			2.8									4.2	1.6					-10.0	-10.0	-19.6
Non-operating income		4.5			4.8									9.3	-0.8					not disclosed		
Non-operating expenses		3.1			2.0									5.1	-2.4					not disclosed		
<b>Ordinary Income</b>	<b>19%</b>	<b>44.8</b>	<b>-36.0%</b>	<b>10%</b>	<b>21.5</b>	<b>-4.6%</b>							<b>15%</b>	<b>66.3</b>	<b>-26.3</b>	<b>-28.4%</b>	<b>74%</b>	<b>10%</b>	<b>90.0</b>	<b>0.0</b>	<b>-41.8</b>	<b>-31.7%</b>
Extraordinary income / losses		-1.1			-3.2									-4.3	-5.8					-4.0	-4.0	7.3
Extraordinary income		1.2			0.7									2.0	-5.6					not disclosed		
Extraordinary losses		2.3			4.0									6.3	0.2					not disclosed		
Income before income taxes and minority interests	19%	43.8	-33.8%	8%	18.3	-34.8%							14%	62.0	-32.1	-34.1%	72%	9%	86.0	-4.0	-34.4	-28.6%
Income taxes / minority interests		18.5			6.5									25.0	-17.0					36.0	-4.0	-14.3
Income taxes		16.4			6.3									22.7	-12.0					not disclosed		
Minority interests		2.1			0.2									2.3	-4.9					not disclosed		
<b>Net Income</b>	<b>11%</b>	<b>25.3</b>	<b>-23.5%</b>	<b>5%</b>	<b>11.7</b>	<b>-38.5%</b>							<b>8%</b>	<b>37.0</b>	<b>-15.1</b>	<b>-29.0%</b>	<b>74%</b>	<b>5%</b>	<b>50.0</b>	<b>0.0</b>	<b>-20.1</b>	<b>-28.7%</b>
Effective tax rate		37%			34%									37%								
Overseas sales ratio results		51%			48%									49%								

### Notes to FY2011 Q2 YTD Results Year-on-Year Comparisons

Net Sales	Plexxikon +4.9, Memaury +3.9, Prasugrel alliance revenue +2.7, Nexium +2.6, Olmesartan +2.2 Ranbaxy -20.3 (appreciation of JPY to INR -8.0), Return of sales rights -15.8, Levofloxacin -7.5, Denosumab milestone payment -5.5, Pravastatin -3.5, Venofer -3.3 (appreciation of JPY to USD and EUR -11.0)
R&D expenses	Forex impact -3.5
Other expenses	Forex Impact -5.5, Cost increase from new subsidiaries including Plexxikon and Kitasato Daiichi Sankyo Vaccine and new product launches
Non-operating income	Decrease in gain on valuation of derivatives of Ranbaxy
Non-operating expenses	Decrease in forex losses of Ranbaxy
Extraordinary income	Decrease in gain on sales of investment securities, and decrease in gain on sales of non-current assets
Extraordinary losses	Decrease in loss on valuation of investment securities was off-set by loss on disaster/loss on abandonment of inventories, and restructuring loss
Income taxes	Decrease in income before income taxes and minority interests Special factors led to improvement in effective tax rate in FY2010 and FY2011 FY2010: Deferred tax accounting applied to loss carried forward taken over through Asubio Pharma reorganization FY2011: Decrease in Ranbaxy's tax expense (Following the redemption of Foreign Currency Convertible Bond, DTA was recognized on redemption premiums charged to previous years' P/Ls under US-GAAP)

### Notes to Revision in FY2011 Forecast

Net Sales	Forex impact -30.0 (appreciation of JPY to USD, EUR, and INR)
SG&A expenses	Forex impact -15.0, cost containment, etc. -10.0
Non-operating items	Forex losses expected from the appreciation of INR to USD
Extraordinary items	Loss on abandonment of inventories, restructuring loss, etc (Gain on sales of certain underutilized real estate, which the Company had expected to occur in Q2, has been carried over to Q4)

## 2. Currency Rate

	Q1		Q2 YTD		Q3 YTD		Q4 YTD		Q2 YTD		FY2011	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Forecast	from Jul
USD/JPY (average)	81.75		79.81				79.81	-9.14	79.81	-9.14	77.00	-5.00
EUR/JPY (average)	117.40		113.78				113.78	-0.06	113.78	-0.06	109.00	-6.00
INR/JPY (average)	1.83		1.83				1.83	-0.18	1.83	-0.18	1.73	-0.17

Appreciation of JPY to USD and EUR negatively affected the FY2011 Q2 YTD results by 11.0 bil yen in net sales and 1.0 bil yen in operating income.

Annual impact of one yen change is estimated to affect the group's FY2011 performance by; USD: net sales 2.4 bil yen, operating income minor / EUR: net sales 0.7 bil yen, operating income 0.1 bil yen

### 3. Segment Information

Daichi Sankyo Group	Q1			Q2			Q3			Q4			Q2 YTD			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		191.9	-4.8%		185.9	-6.5%								377.8	-22.5	-5.6%
Inter-segment sales		0.1			0.1									0.1	0.1	
<b>Net sales</b>	100%	<b>192.0</b>	<b>-4.8%</b>	100%	<b>186.0</b>	<b>-6.4%</b>							100%	<b>378.0</b>	<b>-22.4</b>	<b>-5.6%</b>
Cost of sales	21%	41.1	-8.4%	26%	48.3	-11.2%							24%	89.4	-9.9	-9.9%
Gross Profit	79%	150.8	-3.8%	74%	137.7	-4.6%							76%	288.6	-12.6	-4.2%
SG&A expenses	58%	111.2	-2.0%	64%	119.1	-1.8%							61%	230.3	-4.4	-1.9%
R&D expenses	20%	39.1	-3.1%	22%	40.9	-5.9%							21%	80.0	-3.8	-4.5%
Other expenses	38%	72.1	-1.4%	42%	78.1	+0.5%							40%	150.3	-0.6	-0.4%
<b>Operating Income</b>	21%	<b>39.6</b>	<b>-8.5%</b>	10%	<b>18.7</b>	<b>-19.4%</b>							15%	<b>58.3</b>	<b>-8.2</b>	<b>-12.3%</b>
Non-operating income		3.8			1.7									5.5	1.8	
Non-operating expenses		1.8			1.4									3.3	-0.5	
<b>Ordinary Income</b>	22%	<b>41.6</b>	<b>-4.2%</b>	10%	<b>19.0</b>	<b>-17.8%</b>							16%	<b>60.5</b>	<b>-5.9</b>	<b>-8.9%</b>
Extraordinary income		1.2			0.7									1.8	-2.7	
Extraordinary losses		2.3			3.8									6.1	0.9	
Income before income taxes and minority interests	21%	40.4	+1.2%	9%	15.8	-38.9%							15%	56.3	-9.6	-14.6%
Income taxes		17.8			5.9									23.7	-1.5	
Minority interests		-0.2			-0.8									-1.0	-1.0	
<b>Net Income</b>	12%	<b>22.9</b>	<b>+2.5%</b>	6%	<b>10.7</b>	<b>-41.9%</b>							9%	<b>33.5</b>	<b>-7.1</b>	<b>-17.5%</b>

Ranbaxy Group	Q1			Q2			Q3			Q4			Q2 YTD			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		39.8	-27.5%		38.4	-12.0%								78.2	-20.3	-20.6%
Inter-segment sales		0.2			0.2									0.4	0.3	
<b>Net sales</b>	100%	<b>40.0</b>	<b>-27.1%</b>	100%	<b>38.6</b>	<b>-11.7%</b>							100%	<b>78.6</b>	<b>-20.0</b>	<b>-20.3%</b>
Cost of sales	47%	18.8	-2.2%	54%	20.7	+3.3%							50%	39.5	0.3	+0.6%
Gross Profit	53%	21.2	-40.6%	46%	17.9	-24.5%							50%	39.1	-20.3	-34.1%
SG&A expenses	40%	15.9	-2.6%	42%	16.3	-5.0%							41%	32.2	-1.3	-3.8%
R&D expenses	6%	2.3	-30.8%	6%	2.4	-21.3%							6%	4.7	-1.7	-26.3%
Other expenses	34%	13.7	+4.5%	36%	13.9	-1.4%							35%	27.5	0.4	+1.4%
<b>Operating Income</b>	13%	<b>5.3</b>	<b>-72.7%</b>	4%	<b>1.7</b>	<b>-74.9%</b>							9%	<b>6.9</b>	<b>-19.0</b>	<b>-73.3%</b>
Non-operating income		1.7			3.1									4.9	-2.2	
Non-operating expenses		1.3			0.5									1.8	-2.0	
<b>Ordinary Income</b>	14%	<b>5.8</b>	<b>-79.6%</b>	11%	<b>4.2</b>	<b>+353.5%</b>							13%	<b>10.0</b>	<b>-19.2</b>	<b>-65.8%</b>
Extraordinary income		0.0			0.0									0.0	-5.1	
Extraordinary losses		0.0			0.1									0.1	-0.6	
Income before income taxes and minority interests	14%	5.7	-79.2%	11%	4.2	-31.2%							13%	9.9	-23.8	-70.6%
Income taxes		-1.1			0.6									-0.5	-11.2	
Minority interests		0.0			0.0									0.1	-0.0	
<b>Net Income</b>	17%	<b>6.9</b>	<b>-62.7%</b>	9%	<b>3.5</b>	<b>-22.7%</b>							13%	<b>10.3</b>	<b>-12.5</b>	<b>-54.8%</b>

Inter-segment Transactions	Q1			Q2			Q3			Q4			Q2 YTD			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>		<b>-0.3</b>			<b>-0.3</b>									<b>-0.6</b>		
Cost of sales		0.0			-0.1									-0.1		
Gross Profit		<b>-0.3</b>			<b>-0.2</b>									<b>-0.5</b>		
SG&A expenses		1.1			1.4									2.5		
R&D expenses		-0.4			-0.3									-0.7		
Other expenses		1.4			1.7									3.2		
<b>Operating Income</b>		<b>-1.4</b>			<b>-1.6</b>									<b>-3.0</b>		
Non-operating income		-1.1			-0.1									-1.1		
Non-operating expenses		0.0			0.0									0.1		
<b>Ordinary Income</b>		<b>-2.5</b>			<b>-1.7</b>									<b>-4.2</b>		
Extraordinary income		0.1			0.0									0.1		
Extraordinary losses																
Income before income taxes and minority interests		-2.4			-1.7									-4.1		
Income taxes		-0.3			-0.2									-0.5		
Minority interests		2.3			1.0									3.2		
<b>Net Income</b>		<b>-4.4</b>			<b>-2.4</b>									<b>-6.8</b>		

#### 4. Sales by Business Units

	FY2011		Q1			Q2			Q3			Q4			Q2 YTD				
	Plan *2	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan	
JPY Bn																			
<b>Consolidated Net Sales</b>	<b>970.0</b>	<b>+0.3%</b>	<b>231.7</b>	<b>-9.7%</b>	<b>24%</b>	<b>224.4</b>	<b>-7.5%</b>	<b>23%</b>							<b>456.0</b>	<b>-42.8</b>	<b>-8.6%</b>	<b>47%</b>	
<b>Japan Company (domestic sales)</b>	<b>435.0</b>	<b>+4.6%</b>	<b>100.4</b>	<b>-4.6%</b>	<b>23%</b>	<b>100.5</b>	<b>-2.4%</b>	<b>23%</b>							<b>200.9</b>	<b>-7.3</b>	<b>-3.5%</b>	<b>46%</b>	
Olmotec	93.0	+13.0%	20.4	-1.3%	22%	20.4	-3.1%	22%							40.9	-0.9	-2.2%	44%	
Rezaltas	17.0	+264.3%	2.9	+58.1%	17%	3.2	+3938.1%	19%							6.0	4.1	+219.6%	35%	
Calblock	15.0	+7.5%	3.2	-13.4%	21%	3.2	-9.4%	21%							6.4	-0.8	-11.4%	43%	
Loxonin	58.0	+7.1%	14.4	+10.7%	25%	15.7	+13.3%	27%							30.1	3.2	+12.0%	52%	
Cravit	38.0	+17.4%	8.4	+8.5%	22%	8.4	+11.5%	22%							16.8	1.5	+10.0%	44%	
Mevalotin	32.0	-15.9%	8.8	-14.0%	27%	8.6	-14.4%	27%							17.4	-2.9	-14.2%	54%	
Artist	23.0	-3.0%	6.1	+0.0%	27%	6.2	+6.8%	27%							12.4	0.4	+3.3%	54%	
Omnipaque	23.0	-8.0%	5.7	-11.6%	25%	6.3	-5.1%	27%							11.9	-1.1	-8.3%	52%	
Urief	11.0	+9.4%	2.6	+6.8%	24%	2.8	+13.6%	25%							5.4	0.5	+10.2%	49%	
Inavir	9.0	+35.6%	0.4	-	4%	-0.1	-	-							0.3	0.3	-	3%	
New Memory	not disclosed	-	2.2	-	-	1.6	-	-							3.9	3.9	-	-	
New Nexium	not disclosed	-	-	-	-	2.6	-	-							2.6	2.6	-	-	
Vaccines	not disclosed	-	4.6	+166.4%	-	5.3	+14.8%	-							9.9	3.5	+55.9%	-	
Daiichi Sankyo Espha products	not disclosed	-	2.4	-	-	2.4	-	-							4.8	-	-	-	
<b>Daichi Sankyo Healthcare (OTC)</b>	<b>49.0</b>	<b>+9.3%</b>	<b>9.7</b>	<b>+4.9%</b>	<b>20%</b>	<b>12.7</b>	<b>+8.2%</b>	<b>26%</b>							<b>22.4</b>	<b>1.4</b>	<b>+6.7%</b>	<b>46%</b>	
<b>Daichi Sankyo, Inc. (US)</b>	<b>130.0</b>	<b>-0.4%</b>	<b>34.6</b>	<b>+3.2%</b>	<b>27%</b>	<b>29.7</b>	<b>-12.4%</b>	<b>23%</b>							<b>64.3</b>	<b>-3.1</b>	<b>-4.7%</b>	<b>50%</b>	
Olmesartan	88.0	-6.8%	24.9	-1.5%	28%	20.4	-17.4%	23%							45.3	-4.7	-9.4%	52%	
Benicar/Benicar HCT	67.0	-15.9%	20.1	-6.1%	30%	16.8	-18.7%	25%							36.9	-5.2	-12.3%	55%	
Azor	13.5	+1.5%	3.6	-7.0%	26%	2.5	-26.5%	18%							6.0	-1.2	-16.2%	45%	
Tribenzor	7.5	+415.9%	1.2	-	16%	1.1	+71.6%	15%							2.3	1.7	+252.0%	31%	
Welchol	32.0	+12.2%	7.0	+0.5%	22%	6.5	-11.5%	20%							13.6	-0.8	-5.6%	42%	
Effient (alliance revenue)	not disclosed	-	1.6	+345.5%	-	1.7	+124.3%	-							3.3	2.2	+195.2%	-	
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>49.0</b>	<b>-9.1%</b>	<b>12.7</b>	<b>-13.6%</b>	<b>26%</b>	<b>9.3</b>	<b>-31.7%</b>	<b>19%</b>							<b>22.1</b>	<b>-6.3</b>	<b>-22.3%</b>	<b>45%</b>	
Venofor	25.0	-18.5%	7.4	-12.5%	30%	5.5	-28.5%	22%							12.9	-3.3	-20.2%	52%	
<b>Daichi Sankyo Europe GmbH</b>	<b>77.0</b>	<b>+15.9%</b>	<b>16.9</b>	<b>+14.0%</b>	<b>22%</b>	<b>16.9</b>	<b>+2.0%</b>	<b>22%</b>							<b>33.8</b>	<b>2.4</b>	<b>+7.6%</b>	<b>44%</b>	
Olmesartan	55.0	+19.1%	11.9	+23.5%	22%	12.2	+4.2%	22%							24.0	2.8	+12.9%	44%	
Olmotec/Olmotec Plus	40.0	+9.0%	8.7	+9.8%	22%	8.8	-5.1%	22%							17.5	0.3	+1.8%	44%	
Sevikar	12.0	+43.1%	2.4	+44.1%	20%	2.6	+10.5%	22%							5.0	1.0	+24.4%	42%	
Sevikar HCT	3.0	+172.3%	0.7	-	25%	0.7	-	24%							1.5	1.5	-	49%	
*1 Effient (alliance revenue)	not disclosed	-	0.6	-	-	0.6	-	-							1.2	-	-	-	

	FY2011		Q1			Q2			Q3			Q4			Q2 YTD			
	Plan *2	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
<b>Asia, South and Central America (ASCA)</b>	<b>30.0</b>	<b>+9.3%</b>	<b>6.5</b>	<b>+8.7%</b>	<b>22%</b>	<b>7.3</b>	<b>+3.8%</b>	<b>24%</b>							<b>13.8</b>	<b>0.8</b>	<b>+6.0%</b>	<b>46%</b>
Daiichi Sankyo Pharmaceutical (Beijing)	not disclosed	-	0.9	-19.9%	-	0.9	-15.0%	-							1.8	-0.4	-17.5%	-
Daiichi Sankyo Pharmaceutical (Shanghai)	not disclosed	-	1.7	+21.9%	-	1.7	-3.8%	-							3.4	0.2	+7.9%	-
Daiichi Sankyo Taiwan	not disclosed	-	0.8	+4.6%	-	0.8	-2.8%	-							1.6	0.0	+0.8%	-
Daiichi Sankyo Korea	not disclosed	-	1.2	+23.0%	-	1.1	+27.0%	-							2.4	0.5	+24.9%	-
Daiichi Sankyo (Thailand)	not disclosed	-	0.3	+10.1%	-	0.3	+2.3%	-							0.6	0.0	+5.7%	-
Daiichi Sankyo Brasil Farmacêutica	not disclosed	-	1.1	+2.6%	-	1.5	+4.4%	-							2.6	0.1	+3.7%	-
Daiichi Sankyo Venezuela	not disclosed	-	0.5	+22.5%	-	1.0	+33.2%	-							1.4	0.3	+29.6%	-
<b>Ranbaxy Laboratories Limited</b>	<b>162.0</b>	<b>-5.8%</b>	<b>39.8</b>	<b>-27.5%</b>	<b>25%</b>	<b>38.4</b>	<b>-12.0%</b>	<b>24%</b>							<b>78.2</b>	<b>-20.3</b>	<b>-20.6%</b>	<b>48%</b>
<b>Others</b>	<b>38.0</b>	<b>-32.5%</b>	<b>11.1</b>	<b>-38.7%</b>	<b>29%</b>	<b>9.5</b>	<b>-25.9%</b>	<b>25%</b>							<b>20.5</b>	<b>-10.3</b>	<b>-33.4%</b>	<b>54%</b>
Levofloxacin export, royalty, etc	7.0	-75.1%	3.1	-56.2%	45%	2.3	-67.5%	33%							5.4	-8.8	-61.9%	78%
New Plexxikon	not disclosed	-	3.0	-	-	1.9	-	-							4.9	4.9	-	-

Currency rates for overseas subsidiaries		Q1 Results	Q2 YTD Results	Q3 YTD results	Q4 YTD Results	Q2 YTD Results
	Plan *2					
USD/JPY (average)	83.00	81.75	79.81			79.81
EUR/JPY (average)	115.00	117.40	113.78			113.78
INR/JPY (average)	1.90	1.83	1.83			1.83

**New Product Launches**

May 2011: Sprix (analgesic and anti-inflammatory drug) lunched in US. Sales of Sprix are / will be included in "Luitpold" and "Daiichi Sankyo Inc".

Jun 2011: Memaary (treatment for Alzheimer's Disease) lunched in Japan.

Jul 2011: Lixiana (direct oral factor Xa inhibitor for the prevention of venous thromboembolism after major orthopedic surgery ) lunched in Japan. Sales of Lixiana are included in "Japan Company (domestic sales)".

Aug 2011: Zelboraf (personalized treatment for melanoma) lunched in US. Zelboraf related revenue are / will be included in Plexxikon under "Others".

Sep 2011: Nexium (proton pump inhibitor for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, etc) lunched in Japan.

**Notes**

\*1 Alliance revenue of Efient (Europe) is included in Daiichi Sankyo Europe GmbH from FY2011

\*2 2011 Plan are those announced at the beginning of the fiscal year (May 2011)

**[Reference] Sales in Local Currency**

	FY2011		Q1			Q2			Q3			Q4			Q2 YTD			
	Plan *2	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
USD Mn																		
<b>Daiichi Sankyo, Inc. (US)</b>	<b>1,566</b>	<b>+2.9%</b>	<b>424</b>	<b>+16.1%</b>	<b>27%</b>	<b>382</b>	<b>-2.9%</b>	<b>24%</b>							<b>806</b>	<b>47</b>	<b>+6.3%</b>	<b>52%</b>
Olmesartan	1,060	-3.8%	304	+10.9%	29%	263	-8.4%	25%							567	6	+1.0%	54%
Benicar/Benicar HCT	807	-13.2%	246	+5.7%	31%	217	-10.0%	27%							463	-11	-2.2%	57%
Azor	163	+4.8%	43	+4.7%	27%	32	-18.4%	20%							76	-5	-6.6%	47%
Tribenzor	90	+432.8%	14	-	16%	14	+96.0%	16%							29	22	+292.3%	32%
Welchol	386	+15.9%	86	+13.2%	22%	84	-1.9%	22%							170	8	+5.2%	44%
Effient (alliance revenue)	not disclosed	-	20	+401.5%	-	22	+151.6%	-							41	29	+229.0%	-
USD Mn																		
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>590</b>	<b>-6.1%</b>	<b>156</b>	<b>-2.8%</b>	<b>26%</b>	<b>121</b>	<b>-24.2%</b>	<b>21%</b>							<b>277</b>	<b>-43</b>	<b>-13.4%</b>	<b>47%</b>
Venofor	301	-15.8%	90	-1.5%	30%	71	-20.7%	24%							161	-20	-11.0%	54%
EUR Mn																		
<b>Daiichi Sankyo Europe GmbH</b>	<b>670</b>	<b>+14.1%</b>	<b>144</b>	<b>+13.6%</b>	<b>21%</b>	<b>153</b>	<b>+2.7%</b>	<b>23%</b>							<b>297</b>	<b>21</b>	<b>+7.7%</b>	<b>44%</b>
Olmesartan	478	+17.2%	101	+23.1%	21%	110	+5.1%	23%							211	24	+13.0%	44%
Olmotec/Olmotec Plus	348	+7.3%	74	+9.4%	21%	80	-4.4%	23%							154	3	+1.8%	44%
Sevikar	104	+40.8%	21	+43.7%	20%	24	+11.5%	23%							44	9	+24.4%	42%
Sevikar HCT	26	+167.9%	6	-	24%	6	-	25%							13	13	-	49%
*1 Efient (alliance revenue)	not disclosed	-	5	-	-	6	-	-							11	11	-	-
INR Bn																		
<b>Ranbaxy Laboratories Limited</b>	<b>85</b>	<b>-4.6%</b>	<b>22</b>	<b>-21.5%</b>	<b>26%</b>	<b>21</b>	<b>-1.5%</b>	<b>25%</b>							<b>43</b>	<b>-6</b>	<b>-12.8%</b>	<b>50%</b>



## 5. Sales of Global Products

	FY2011		Q1			Q2			Q3			Q4			Q2 YTD				
	Plan *2	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan	
JPY Bn																			
<b>Olmesartan</b>	<b>270.0</b>	<b>+11.8%</b>	<b>63.3</b>	<b>+5.2%</b>	<b>24%</b>	<b>60.4</b>	<b>-1.6%</b>	<b>22%</b>							<b>123.8</b>	<b>2.2</b>	<b>+1.8%</b>	<b>46%</b>	
Olmetec (JPN)	93.0	+13.0%	20.4	-1.3%	22%	20.4	-3.1%	22%							40.9	-0.9	-2.2%	44%	
Rezaltas (JPN)	17.0	+264.3%	2.9	+58.1%	17%	3.2	+3938.1%	19%							6.0	4.1	+219.6%	35%	
Benicar/Benicar HCT (US)	67.0	-15.9%	20.1	-6.1%	30%	16.8	-18.7%	25%							36.9	-5.2	-12.3%	55%	
Azor (US)	13.5	+1.5%	3.6	-7.0%	26%	2.5	-26.5%	18%							6.0	-1.2	-16.2%	45%	
Tribenzor (US)	7.5	+415.9%	1.2	-	16%	1.1	+71.6%	15%							2.3	1.7	+252.0%	31%	
Olmetec/Olmetec Plus (EU)	40.0	+9.0%	8.7	+9.8%	22%	8.8	-5.1%	22%							17.5	0.3	+1.8%	44%	
Sevikar (EU)	12.0	+43.1%	2.4	+44.1%	20%	2.6	+10.5%	22%							5.0	1.0	+24.4%	42%	
Sevikar HCT (EU)	3.0	+172.3%	0.7	-	25%	0.7	-	24%							1.5	1.5	-	49%	
Other subsidiaries, export, etc	17.0	+22.0%	3.3	+16.4%	20%	4.3	+10.4%	25%							7.6	0.9	+13.0%	45%	
<b>Levofloxacin</b>	<b>53.0</b>	<b>-23.3%</b>	<b>13.5</b>	<b>-20.2%</b>	<b>26%</b>	<b>12.8</b>	<b>-24.1%</b>	<b>24%</b>							<b>26.4</b>	<b>-7.5</b>	<b>-22.2%</b>	<b>50%</b>	
Cravit (JPN)	38.0	+17.4%	8.4	+8.5%	22%	8.4	+11.5%	22%							16.8	1.5	+10.0%	44%	
Export, royalty, etc	7.0	-75.1%	3.1	-56.2%	45%	2.3	-67.5%	33%							5.4	-8.8	-61.9%	78%	
Other subsidiaries	8.0	-7.7%	2.0	-4.7%	25%	2.1	-4.9%	26%							4.1	-0.2	-4.8%	51%	
<b>Pravastatin</b>	<b>38.0</b>	<b>-15.3%</b>	<b>10.2</b>	<b>-13.9%</b>	<b>27%</b>	<b>10.0</b>	<b>-15.5%</b>	<b>26%</b>							<b>20.2</b>	<b>-3.5</b>	<b>-14.7%</b>	<b>53%</b>	
Mevalotin (JPN)	32.0	-15.9%	8.8	-14.0%	27%	8.6	-14.4%	27%							17.4	-2.9	-14.2%	54%	
Other subsidiaries, export, etc	6.0	-11.9%	1.5	-12.9%	25%	1.3	-22.1%	22%							2.8	-0.6	-17.5%	47%	
<b>Prasugrel (alliance revenue)</b>	<b>not disclosed</b>	<b>-</b>	<b>2.2</b>	<b>+176.5%</b>	<b>-</b>	<b>2.3</b>	<b>+134.2%</b>	<b>-</b>							<b>4.5</b>	<b>2.7</b>	<b>+152.9%</b>	<b>-</b>	
Effient alliance revenue (US)	not disclosed	-	1.6	+345.5%	-	1.7	+124.3%	-							3.3	2.2	+195.2%	-	
Efient alliance revenue (EU)	not disclosed	-	0.6	+34.9%	-	0.6	+165.9%	-							1.2	0.5	+81.8%	-	

## 6. Number of Employees

	Mar 2011 Results	Jun 2011 Results	Sep 2011 Results	Dec 2011 Results	Mar 2012 Results
<b>Total Number of Employees</b>	<b>30,488</b>	<b>31,556</b>	<b>31,572</b>		
Japan	9,002	9,402	9,359		
* Overseas	21,486	22,154	22,213		
Daiichi Sankyo Group	17,065	17,771	17,777		
* Ranbaxy Group	13,423	13,785	13,795		

\* For overseas subsidiaries with different fiscal year-ends, numbers as of Jun-end are shown in the Sep-end columns

## 7. Management / Financial Indicators

	FY2009 Results	FY2010 Q2 YTD Results	FY2010 Results	FY2011 Q2 YTD Results	FY2011 Forecast
<b>Management Indicators</b>					
Earnings per share (EPS)	59.5 Yen	74.1 Yen	99.6 Yen	52.6 Yen	71.0 Yen
Dividend per share	60.0 Yen	30.0 Yen	60.0 Yen	30.0 Yen	60.0 Yen
Dividend payout ratio (Consolidated)	100.9 %	40.5 %	60.2 %	57.0 %	84.5 %
Return on equity (ROE)	4.9 %	- %	8.2 %	4.4 %	
Dividend on equity (DOE)	4.9 %	- %	5.0 %	2.5 %	
Book value per share (BPS)	1,215.6 Yen	1,212.7 Yen	1,206.1 Yen	1,196.1 Yen	
Equity ratio	57.4 %	58.3 %	57.4 %	57.2 %	
Number of treasury stock purchased	-	-	-	-	
Total number of common shares	704 million	704 million	704 million	704 million	
Share price at end of period	1,751 Yen	1,698 Yen	1,606 Yen	1,620 Yen	
Market value	1,232.6 JPY Bn	1,195.3 JPY Bn	1,130.4 JPY Bn	1,140.3 JPY Bn	
<b>Financial Indicators</b>					
Total assets	1,489.5 JPY Bn	1,465.0 JPY Bn	1,480.2 JPY Bn	1,472.2 JPY Bn	
Current assets	819.8 JPY Bn	843.6 JPY Bn	894.1 JPY Bn	788.0 JPY Bn	
*1 Liquidity on hand	358.3 JPY Bn	401.0 JPY Bn	426.8 JPY Bn	299.7 JPY Bn	
Debt with interest	290.9 JPY Bn	299.4 JPY Bn	299.4 JPY Bn	260.7 JPY Bn	
Equity capital	855.7 JPY Bn	853.6 JPY Bn	849.0 JPY Bn	842.0 JPY Bn	
Cash flow from operating activities	130.2 JPY Bn	77.3 JPY Bn	141.1 JPY Bn	46.0 JPY Bn	
Cash flow from investing activities	42.6 JPY Bn	-25.2 JPY Bn	-63.0 JPY Bn	-84.8 JPY Bn	
Cash flow from financial activities	-89.1 JPY Bn	-10.8 JPY Bn	-26.0 JPY Bn	-50.3 JPY Bn	
*2 Free cash flow	172.9 JPY Bn	52.1 JPY Bn	78.2 JPY Bn	-38.8 JPY Bn	
Cash and cash equivalents, end of period	259.2 JPY Bn	291.0 JPY Bn	302.4 JPY Bn	205.1 JPY Bn	
<b>Others</b>					
Number of consolidated subsidiaries	99	98	101	102	

\*1 Current deposits + marketable securities + investment securities, etc

2 Cash flow from operating activities and investing activities

## 8. Capital Expenditure and Depreciation and Amortization Expenses

	FY2009 Results	FY2010 Q2 YTD Results	FY2010 Results	FY2011 Q2 YTD Results	FY2011 Plan
Capital expenditure	29.7 JPY Bn	15.3 JPY Bn	37.3 JPY Bn	20.4 JPY Bn	50.0 JPY Bn
Depreciation and amortization expense	45.9 JPY Bn	21.3 JPY Bn	43.9 JPY Bn	21.8 JPY Bn	46.0 JPY Bn
Tangible assets	28.8 JPY Bn	12.9 JPY Bn	27.5 JPY Bn	13.6 JPY Bn	
Intangible assets	17.1 JPY Bn	8.4 JPY Bn	16.5 JPY Bn	8.2 JPY Bn	

## 9. Consolidated Balance Sheets

(Millions of yen\*)

	Mar 2011	Sep 2011	YoY	Notes
<b>ASSETS</b>				
Current assets				
Cash and time deposits	262,037	84,858	-177,179	PBT +62.0 Bn, Plexxikon acquisition -72.0 Bn, Loans / Bonds -40.0 Bn Dividend paid -21.7 Bn, Income taxes paid -18.7 Bn
Trade notes and accounts receivable	205,590	207,045	1,455	
Marketable securities	157,653	203,098	45,445	
Merchandise and finished goods	89,143	102,176	13,033	Addition of Kitasato Daiichi Sankyo Vaccine (KDSV), etc
Work in process	21,598	22,353	755	
Raw materials and supplies	32,050	34,366	2,316	
Deferred tax assets	90,245	95,688	5,443	
Other current assets	38,075	40,991	2,916	
Allowance for doubtful accounts	-2,319	-2,566	-247	
Total current assets	894,075	788,011	-106,064	
Non-current assets				
Property, plant and equipment				
Buildings and structures, net	119,962	125,023	5,061	
Machinery, equipment and vehicles, net	46,706	48,019	1,313	
Land	38,407	38,334	-73	
Construction in progress	20,599	25,946	5,347	
Other, net	12,034	12,151	117	
Total property, plant and equipment	237,710	249,475	11,765	Addition of KDSV +7.9 Bn
Intangible assets				
Goodwill, net	67,316	87,049	19,733	Newly added: Plexxikon +25.6 Bn, KDSV +2.3 Bn
Other intangible assets, net	89,606	158,422	68,816	Newly added: Plexxikon +81.1 Bn, KDSV +2.6 Bn
Total intangible assets	156,923	245,471	88,548	
Investments and other assets				
Investment securities	102,416	108,295	5,879	
Deferred tax assets	73,245	66,855	-6,390	
Other	16,149	14,339	-1,810	
Allowance for doubtful accounts	-281	-292	-11	
Total investments and other assets	191,531	189,196	-2,335	
Total non-current assets	586,164	684,143	97,979	
<b>Total assets</b>	<b>1,480,240</b>	<b>1,472,155</b>	<b>-8,085</b>	

\* All amounts have been rounded down to the nearest million yen

(Millions of yen\*)

	Mar 2011	Sep 2011	YoY	Notes
<b>LIABILITIES</b>				
Current liabilities				
Trade notes and accounts payable	58,407	59,171	764	
Current portion of convertible bond-type bonds with subscription rights to shares	46,020	—	-46,020	Redeemed in Mar-2011
Short-term bank loans	29,342	33,189	3,847	
Income taxes payable	7,545	8,162	617	
Allowance for sales returns	1,244	780	-464	
Allowance for sales rebates	1,623	2,001	378	
Provision for loss on disaster	4,570	3,997	-573	
Asset retirement obligations	178	196	18	
Other current liabilities	158,019	147,934	-10,085	
<b>Total current liabilities</b>	<b>306,952</b>	<b>255,433</b>	<b>-51,519</b>	
Long-term liabilities				
Bonds payable	100,000	100,000	—	
Long-term debt	124,036	127,527	3,491	
Deferred tax liabilities	28,463	57,675	29,212	DTL on the purchase price allocation of Plexxikon +30.3 Bn
Accrued employees' severance and retirement benefits	11,541	13,279	1,738	
Accrued directors' severance and retirement benefits	155	150	-5	
Other long-term liabilities	21,388	23,735	2,347	
<b>Total long-term liabilities</b>	<b>285,585</b>	<b>322,368</b>	<b>36,783</b>	
<b>Total liabilities</b>	<b>592,537</b>	<b>577,802</b>	<b>-14,735</b>	
<b>NET ASSETS</b>				
Shareholders' equity				
Common stock	50,000	50,000	—	
Capital surplus	105,194	105,194	—	
Retained earnings	774,274	790,202	15,928	Net Income +37.0 Bn, Dividend paid -21.1 Bn
Treasury stock, at cost	-14,581	-14,585	-4	
<b>Total shareholders' equity</b>	<b>914,888</b>	<b>930,810</b>	<b>15,922</b>	
Accumulated other comprehensive income				
Net unrealized gain on investment securities	16,559	16,344	-215	
Deferred gains or losses on hedges	1,193	1,318	125	
Foreign currency translation adjustments	-83,636	-106,511	-22,875	Decrease in net assets of overseas subsidiaries in JPY basis -22.9 Bn
<b>Total accumulated other comprehensive income</b>	<b>-65,883</b>	<b>-88,848</b>	<b>-22,965</b>	
Subscription rights to shares	3,544	3,849	305	
Minority interests	35,153	48,540	13,387	Investment in KDSV from The Kitasato Institute (49%) +10.3 Bn
<b>Total net assets</b>	<b>887,702</b>	<b>894,352</b>	<b>6,650</b>	
<b>Total liabilities and net assets</b>	<b>1,480,240</b>	<b>1,472,155</b>	<b>-8,085</b>	

\* All amounts have been rounded down to the nearest million yen

## 10. Consolidated Statements of Cash Flows

(Millions of yen\*)

	FY2010 Q2 YTD Results	FY2011 Q2 YTD Results	YoY	Notes
Cash flows from operating activities				
Income before income taxes and minority interests	94,129	62,049	-32,080	
Depreciation	21,296	21,845	549	
Loss on impairment of long-lived assets	682	311	-371	
Amortization of goodwill	4,533	5,619	1,086	
(Gain) loss on valuation of derivatives	-4,690	-2,371	2,319	
Increase (decrease) in allowance for doubtful accounts	33	281	248	
Increase (decrease) in accrued severance and retirement benefits	645	794	149	
(Increase) decrease in prepaid pension costs	1,141	939	-202	
Interest and dividend income	-3,105	-2,977	128	
Interest expense	2,992	2,971	-21	
Foreign exchange (gains) losses	2,019	1,100	-919	
(Gain) loss on valuation of investment securities	3,228	111	-3,117	
(Gain) loss on sales of investment securities	-2,862	—	2,862	
(Gain) loss on sales of investments in affiliates	-33	—	33	
(Gain) loss on sales and disposal of property, plant and equipment	-3,835	-711	3,124	
Equity in net (income) losses of affiliated companies	214	41	-173	
(Increase) decrease in trade notes and accounts receivable	-3,041	-2,395	646	
(Increase) decrease in inventories	-3,759	-17,968	-14,209	
Increase (decrease) in trade notes and accounts payable	3,270	1,661	-1,609	
Increase (decrease) in accounts payable and accrued expenses	-6,515	-7,189	-674	
Other, net	-9,819	-1,510	8,309	
Subtotal	96,523	62,603	-33,920	
Interest and dividends received	3,227	4,546	1,319	
Interest paid	-1,664	-2,517	-853	
Income taxes paid	-20,758	-18,658	2,100	
Net cash provided by operating activities	77,327	45,972	-31,355	

\* All amounts have been rounded down to the nearest million yen


(Millions of yen\*)

	FY2010 Q2 YTD Results	FY2011 Q2 YTD Results	YoY	Notes
<b>Cash flows from investing activities</b>				
Payments into time deposits	-52,064	-11,695	40,369	
Proceeds from maturities in time deposits	29,670	48,356	18,686	
Purchases of marketable securities	-53,355	-73,235	-19,880	
Proceeds from sales of marketable securities	54,998	68,089	13,091	
Acquisitions of property, plant and equipment	-15,385	-21,424	-6,039	
Proceeds from sales of property, plant and equipment	8,034	4,227	-3,807	
Acquisitions of intangible assets	-2,586	-4,451	-1,865	
Acquisitions of investment securities	-745	-6,810	-6,065	
Proceeds from sales of investment securities	4,767	—	-4,767	
Acquisition of investments in subsidiaries	-1,871	-34	1,837	FY2010: Zenotech
Acquisition of investments in subsidiaries resulting in change in scope of consolidation	—	-71,958	-71,958	Plexxikon
Proceeds from sales of investments in subsidiaries resulting in changes in scope of consolidation	5,641	—	-5,641	Transfer of Shizuoka Factory
Payment for loans receivable	-0	—	0	
Proceeds from collection of loans receivable	3	—	-3	
Payments for transfer of business	—	-16,096	-16,096	Kitasato Daiichi Sankyo Vaccine (KDSV)
Other, net	-2,292	269	2,561	
<b>Net cash provided by (used in) investing activities</b>	<b>-25,185</b>	<b>-84,763</b>	<b>-59,578</b>	
<b>Cash flows from financing activities</b>				
Net increase (decrease) in short-term bank loans	12,626	3,887	-8,739	
Proceeds from long-term debt	—	7,412	7,412	
Repayments of long-term debt	-2,371	-3,628	-1,257	
Redemption of bonds	—	-47,643	-47,643	Redemption of Ranbaxy's Foreign Currency Convertible Bond
Proceeds from stock issuance to minority shareholders	—	11,270	11,270	Investment in KDSV from The Kitasato Institute (49%)
Purchases of treasury stock	-12	-7	5	
Proceeds from sale of treasury stock	1	1	0	
Dividends paid	-21,117	-21,112	5	
Other, net	39	-486	-525	
<b>Net cash used in financing activities</b>	<b>-10,833</b>	<b>-50,306</b>	<b>-39,473</b>	
Effect of exchange rate changes on cash and cash equivalents	-9,543	-8,216	1,327	
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>31,764</b>	<b>-97,313</b>	<b>-129,077</b>	
Cash and cash equivalents, beginning of year	259,215	302,402	43,187	
Cash and cash equivalents, at end of year	290,980	205,089	-85,891	

\* All amounts have been rounded down to the nearest million yen

11. Major R&D Pipeline

October 2011

Therapeutic Area	Phase1	Phase2	Phase3	Application
Cardiovascular-Metabolics	<p><b>CS-3150</b> (Antihypertensive)</p> <p><b>DS-7309</b> (Anti-diabetes)</p>	<p><b>DU-176b (US/EU)</b> (Edoxaban / post-surgical VTE / oral factor Xa inhibitor)</p> 	<p><b>DU-176b (US/EU/JP/Asia)</b> (Edoxaban / AF / oral factor Xa inhibitor)</p> <p><b>DU-176b (US/EU/JP/Asia)</b> (Edoxaban / VTE / oral factor Xa inhibitor)</p> <p><b>CS-747 (US/EU/Asia)</b> (Prasugrel / ACS-MM / anti-platelet agent)</p> <p><b>CS-747 (JP)</b> (Prasugrel / ACS-PCI / anti-platelet agent)</p> <p><b>CS-747 (JP)</b> (Prasugrel / ischemic stroke / anti-platelet agent)</p>	
Oncology	<p><b>CS-7017 (JP/Asia)</b> (Efatutazone / PPARγ agonist)</p> <p><b>U3-1565 (US/JP)</b> (Anti-HB-EGF antibody)</p> <p><b>U3-1287 (JP)</b> (Anti-HER3 antibody)</p> <p><b>DS-2248 (US)</b> (Hsp90 inhibitor)</p> <p><b>DS-7423 (US)</b> (PI3K/mTOR inhibitor)</p>	<p><b>U3-1287 (US/EU)</b> (Anti-HER3 antibody)</p> <p><b>CS-1008 (US/EU/JP/Asia)</b> (Tigatuzumab / anti-DR5 antibody)</p> <p><b>CS-7017 (US/EU)</b> (Efatutazone / PPARγ agonist)</p> <p><b>DE-766 (JP)</b> (Nimotuzumab / anti-EGFR antibody)</p> <p><b>PLX3397 (US)</b> (Fms/Kit/Flt3-ITD inhibitor)</p>	<p><b>ARQ 197 (US/EU)</b> (Tivantinib / NSCLC / c-Met inhibitor)</p> <p><b>AMG 162 (JP)</b> (Denosumab / osteoporosis, breast cancer adjuvant / anti-RANKL antibody)</p>	<p><b>PLX4032 (US)</b> → (Vemurafenib / Melanoma / BRAF inhibitor)</p> <p><b>PLX4032 (EU)</b> (Vemurafenib / Melanoma / BRAF inhibitor)</p> <p><b>AMG 162 (JP)</b> (Denosumab / bone metastases of cancer / anti-RANKL antibody)</p>
Infectious diseases	<p><b>CS-8958 (US/EU)</b> (Laninamivir / anti-influenza / co-development with Biota)</p> <p><b>CS-4771</b> (Anti-Sepsis)</p> <p><b>DS-8587</b> (Broad spectrum antibacterial agent)</p>		<p><b>CS-8958 (JP)</b> (Laninamivir / anti-influenza, prophylactic / Neuraminidase inhibitor)</p>	
Bone/Joint diseases	<p><b>PLX5622</b> (Rheumatoid arthritis)</p>	<p><b>AMG 162 (JP)</b> (Denosumab / rheumatoid arthritis / anti-RANKL antibody)</p>	<p><b>AMG 162 (JP)</b> (Denosumab / osteoporosis / anti-RANKL antibody)</p>	
Immunological allergic diseases	<p><b>CS-0777</b> (Immunomodulator)</p>	<p><b>SUN13834 (US)</b> (Chymase inhibitor)</p>		
Others	<p><b>DS-5565</b> (Chronic pain)</p> <p><b>SUN13837</b> (Spinal cord injury)</p>	<p><b>SUN11031 (US/EU)</b> (Human ghrelin / COPD cachexia)</p>	<p><b>SUN11031 (JP)</b> (Human ghrelin / anorexia nervosa)</p> <p><b>DD-723-B (JP)</b> (Perflubutane / Contrast agents in ultrasound for prostate cancer and breast tumor/ ultrasound contrast agent)</p>	<p><b>KMD-3213 (China)</b> → (Silodosin / treatment of dysuria associated with benign prostatic hyperplasia/ Selective alpha 1A blocker)</p>



## Change from the announcement in July 2011

### **# Change of Stage**

PLX4032 (Melanoma/BRAF inhibitor/US/approved)  
KMD-3213 (Treatment of dysuria associated with benign prostatic/China/approved)  
CS-747 (Ischemic stroke/anti-platelet/JP/P3)

### **# Discontinued**

DU-176b (Post surgical VTE/oral factor Xa inhibitor/US-EU/P2)  
SUN11031 (COPD cachexia/US-EU/P2)

## Cardiovascular-Metabolics

[ project after Phase II ]

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
DU-176b	edoxaban	Oral	Factor Xa inhibitor	1) Atrial fibrillation (AF) 2) Venous thromboembolism (VTE) 3) Post surgical VTE	Daiichi Sankyo	US/EU JP Asia	1)P3, 2)P3, 3) - 1)P3, 2)P3, 3) Approved 1)P3, 2)P3, 3) -
<ul style="list-style-type: none"> <li>An oral anticoagulant that specifically, reversibly and directly inhibits Xa factor playing an important role in the process when blood coagulates.</li> <li>An oral factor Xa inhibitor, possible once daily regimen with high oral absorption, confirmed by clinical trials.</li> <li>No severe hepatotoxicity signals in pre-clinical and clinical trials</li> <li>Development by Daiichi Sankyo globally               <ul style="list-style-type: none"> <li>A P3 multi-national trial in AF, completed its patient enrollment in Nov-2010. (ENGAGE AF-TIMI48)</li> <li>A P3 multi-national trial for prevention of recurrent VTE in patients with deep-vein thrombosis and/or pulmonary embolism started in Jan-2010.(HOKUSAI VTE)</li> </ul> </li> <li>[JP] Launched for the prevention of VTE after major orthopedic surgery in July-2011. Brand name: Lixiana</li> </ul>							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-747	prasugrel	Oral	Anti-platelet agent	1) Acute coronary syndrome(ACS-PCI) 2) Acute coronary syndrome(ACS-MM) 3) Ischemic stroke	Daiichi Sankyo Ube Industries	US/EU/Asia JP	1) Approved, 2)P3, 3)- 1) P3, 2) -, 3)P3
<ul style="list-style-type: none"> <li>Inhibition platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface.</li> <li>Co-development with Eli Lilly in the US and EU, development by Daiichi Sankyo in Japan</li> <li>In June, 2008, a new P3 trial (TRILOGY ACS) started for patients with acute coronary syndrome, not being managed with percutaneous coronary intervention (ACS-MM).</li> <li>[EU] Approved in Feb-2009 for ACS-PCI. Brand name: Effient</li> <li>[US] Approved in Jul-2009 for ACS-PCI. Brand name: Effient</li> <li>[JP] P3 studies for ACS-PCI, elective PCI and ischemic stroke are on-going.</li> </ul>							

## Oncology

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
ARQ 197	tivantinib	Oral	c-Met inhibitor	-	ArQule	US/EU	P3
<ul style="list-style-type: none"> <li>c-Met has multiple roles in intracellular signal transductions such as cancer cell motility, proliferation, angiogenesis, invasion, and apoptosis induction.</li> <li>Variations of c-Met are shown in gastric, HCC, head and neck cancer, and high expression of c-met are shown in colon, HCC, pancreatic, prostate, breast cancer, etc.</li> <li>Clinical studies are on-going for several types of cancer.</li> <li>A P3 clinical study for NSCLC is on-going.</li> </ul>							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-1008	tigatuzumab	Injection	Anti-DR5 antibody	-	Daiichi Sankyo	US/EU JP/Asia	P2
<ul style="list-style-type: none"> <li>A humanized version TRA-8, a murine agonistic Mab raised against human death receptor 5(DR5).</li> <li>DR5 is rarely expressed in normal tissues, expected to show selective activity against tumor cells.</li> <li>Induces apoptosis of tumor cells expressing DR5 on the cell surface.</li> <li>Clinical studies are on-going for several types of cancer.</li> </ul>							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
DE-766	nimotuzumab	Injection	Anti-EGFR antibody	-	CIMYM Biosciences	JP	P2
<ul style="list-style-type: none"> <li>• A humanized monoclonal antibody against Epidermal Growth Factor Receptor(EGFR).</li> <li>• Expected to be a best in class EGFR antibody, safety against the skin toxicity and the efficacy comparable to the other EGFR antibodies.</li> <li>• Clinical studies are on-going for several types of cancer.</li> </ul>							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-7017	efatutazone	Oral	PPAR-gamma agonist	-	Daiichi Sankyo	US/EU JP/Asia	P2 P1
<ul style="list-style-type: none"> <li>• Inhibits growth of tumor cells in vitro without killing those cells.</li> <li>• Expected to be less toxic compared to standard chemotherapeutics.</li> <li>• Clinical studies are on-going for several types of cancer.</li> </ul>							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
U3-1287	-	Injection	Anti-HER3 antibody	-	Daiichi Sankyo (U3 Pharma)	US/EU JP	P2 P1
<ul style="list-style-type: none"> <li>• HER3 is one of the member of the Epidermal Growth Factor Receptor(EGFR) family of proteins.</li> <li>• HER3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are more potent to induce cell proliferation than homodimers of HER2 or EGFR</li> <li>• Clinical studies are on-going for several types of cancer.</li> </ul>							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
PLX4032	vemurafenib	Oral	BRAF inhibitor	-	Daiichi Sankyo (Plexxikon)	US EU	Approved Application
<ul style="list-style-type: none"> <li>• Plexxikon discovered vemurafenib, and since 2006, has been co-developing it with partner, Roche</li> <li>• Personalized treatment for patients with unresectable (inoperable) or metastatic melanoma with a BRAFV600E mutation as detected by an FDA-approved test.</li> </ul>							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
PLX3397	-	Oral	Fms/Kit/Flt3-ITD inhibitor	-	Daiichi Sankyo (Plexxikon)	US	P2
<ul style="list-style-type: none"> <li>• A P2 clinical trial for Hodgkin's lymphoma is on-going.</li> <li>• Clinical studies are planned for several types of cancer.</li> </ul>							

## Infectious diseases

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-8958	Ianinamivir	Inhalant	Neuraminidase inhibitor	Influenza, 1) Treatment, 2) Prophylactic	Daiichi Sankyo	US/EU JP	P1 1) Approved, 2) P3
<ul style="list-style-type: none"> <li>• Long-acting neuraminidase inhibitor</li> <li>• Licensing activity with Biota in the US and EU, development by Daiichi Sankyo in Japan</li> <li>• CS-8958 is under development as an inhalant that will act directly on the pulmonary and tracheal sites of infection.</li> <li>• P3 for the flu prophylactic in Japan</li> <li>• [JP] Approved for the flu treatment: Sep-2010. Brand name: Inavir</li> </ul>							

## Bone/Joint diseases

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
AMG 162	denosumab	Injection	Anti-RANKL antibody	1) Bone metastases of cancer 2) Osteoporosis 3) Breast cancer adjuvant 4) Rheumatoid arthritis	Amgen	JP	1) Application 2,3) P3 4)P2
<ul style="list-style-type: none"> <li>• Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (RANKL), a key mediator of the resorptive phase of bone remodeling.</li> <li>• July, 2007 In-licensed from Amgen</li> <li>• P3 : Osteoporosis, Breast cancer adjuvant, P2: Rheumatoid arthritis</li> <li>• Application: Bone metastases of cancer in Aug-2010</li> </ul>							

## Immunological allergic diseases

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
SUN 13834	-	Oral	Chymase inhibitor	Atopic Dermatitis	Daiichi Sankyo (Asubio Pharma)	US	P2
<ul style="list-style-type: none"> <li>• Inhibiting chymase, one of endogenous proteases, which is released from mast cells and involves allergic reaction.</li> <li>• Expected to be an oral anti-atopic dermatitis drug with a novel mechanism of action.</li> </ul>							

## Others

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
KMD-3213	silodosin	Oral	Selective alpha 1A blocker	Treatment of dysuria associated with benign prostatic hyperplasia	Kissei	China	Approved
<ul style="list-style-type: none"> <li>• An alpha1A blocker which effectively reduces urinary tract resistance and improves dysuria associated with benign prostatic hyperplasia.</li> <li>• Reduces cardiovascular side effects due to its alpha1A selectivity.</li> <li>• Silodosin is marketed in Japan as brand name of URIEF by Daiichi Sankyo and Kissei.</li> <li>• Approved in China: Aug-2011</li> </ul>							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
SUN 11031	human ghrelin	Injection	Appetite stimulation/ Increase gastric motility	Anorexia Nervosa	Daiichi Sankyo (Asubio Pharma)	JP	P3
<ul style="list-style-type: none"> <li>• Ghrelin is an endogenous peptide known as one-and-only peripheral appetite stimulator among all hormones discovered the relationship with feeding behavior up to now. In addition to it, ghrelin is a potent stimulator of growth hormone release.</li> <li>• A P3 study for anorexia nervosa in Japan is on-going.</li> </ul>							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
DD-723-B	perflubutane	Injection	Ultrasound contrast agent	Contrast for prostatic tumor Contrast for mammary tumor	GEHC	JP	P3 P3
<ul style="list-style-type: none"> <li>• DD-723-B is marketed in Japan as a brand name of Sonazoid for injection.</li> </ul>							

**1. Summary of Consolidated Income Statement (FY2010)**

JPY Bn	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>256.4</b>	<b>+12.9%</b>	<b>100%</b>	<b>242.5</b>	<b>-0.4%</b>	<b>100%</b>	<b>249.2</b>	<b>-2.3%</b>	<b>100%</b>	<b>219.3</b>	<b>-3.2%</b>	<b>100%</b>	<b>967.4</b>	<b>15.3</b>	<b>+1.6%</b>
Cost of sales	25%	64.1	+2.5%	31%	74.4	-0.4%	30%	74.6	-1.1%	31%	68.6	+5.0%	29%	281.7	3.6	+1.3%
Gross Profit	75%	192.4	+16.9%	69%	168.0	-0.4%	70%	174.6	-2.8%	69%	150.7	-6.4%	71%	685.7	11.6	+1.7%
SG&A expenses	51%	131.3	-4.7%	57%	139.0	-3.9%	58%	144.1	+2.6%	68%	149.2	-4.1%	58%	563.5	-15.0	-2.6%
R&D expenses	17%	43.6	-3.4%	19%	45.7	-6.7%	21%	53.0	+11.4%	24%	52.0	-5.6%	20%	194.3	-2.5	-1.3%
Other expenses	34%	87.7	-5.4%	38%	93.3	-2.5%	37%	91.1	-2.0%	44%	97.2	-3.3%	38%	369.2	-12.5	-3.3%
<b>Operating Income</b>	<b>24%</b>	<b>61.1</b>	<b>+128.1%</b>	<b>12%</b>	<b>29.0</b>	<b>+20.6%</b>	<b>12%</b>	<b>30.5</b>	<b>-22.2%</b>	<b>1%</b>	<b>1.5</b>	<b>-72.2%</b>	<b>13%</b>	<b>122.1</b>	<b>26.6</b>	<b>+27.9%</b>
Non-operating income / expenses		9.0			-6.5			7.4			-0.4			9.6	2.0	
Non-operating income		11.8			-1.7			7.5			5.6			23.2	-5.0	
Non-operating expenses		2.8			4.8			0.0			6.0			13.6	-7.0	
<b>Ordinary Income</b>	<b>27%</b>	<b>70.1</b>	<b>+877.7%</b>	<b>9%</b>	<b>22.6</b>	<b>-50.0%</b>	<b>15%</b>	<b>38.0</b>	<b>-1.1%</b>	<b>1%</b>	<b>1.2</b>	<b>-90.7%</b>	<b>14%</b>	<b>131.8</b>	<b>28.6</b>	<b>+27.8%</b>
Extraordinary income / losses		-4.0			5.5			-1.2			-11.6			-11.3	-5.6	
Extraordinary income		0.8			6.8			0.9			4.3			12.8	6.9	
Extraordinary losses		4.8			1.3			2.2			15.9			24.2	12.5	
Income before income taxes and minority interests	26%	66.1	+665.1%	12%	28.0	-37.7%	15%	36.7	-1.6%	-5%	-10.4	-	12%	120.4	23.0	+23.7%
Income taxes / minority interests		33.0			9.0			9.2			-0.9			50.3	-5.2	
Income taxes		26.6			8.2			8.0			-0.9			41.8	-8.2	
Minority interests		6.5			0.8			1.2			0.0			8.5	3.0	
<b>Net Income</b>	<b>13%</b>	<b>33.1</b>	<b>-</b>	<b>8%</b>	<b>19.1</b>	<b>-24.1%</b>	<b>11%</b>	<b>27.5</b>	<b>+33.8%</b>	<b>-4%</b>	<b>-9.5</b>	<b>-</b>	<b>7%</b>	<b>70.1</b>	<b>28.3</b>	<b>+67.5%</b>
Effective tax rate		40%			29%			22%			-			35%		
Overseas sales ratio results		52%			51%			46%			53%			51%		

**2. Currency Rate (FY2010)**

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2010	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	92.02	88.95	86.53	85.72	85.72	-7.14
EUR/JPY (average)	117.00	113.84	113.31	113.13	113.13	-18.03
INR/JPY (average)	1.98	2.01	1.96	1.93	1.93	-0.02

**3. Segment Information (FY2010)**

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	100%	<b>201.6</b>	<b>+2.1%</b>	100%	<b>198.8</b>	<b>-4.0%</b>	100%	<b>213.7</b>	<b>-2.4%</b>	100%	<b>181.3</b>	<b>-0.3%</b>	100%	<b>795.5</b>	<b>-10.0</b>	<b>-1.2%</b>
Cost of sales	22%	44.9	-1.1%	27%	54.4	+0.1%	26%	55.0	-1.1%	26%	47.6	+0.5%	25%	201.8	-0.8	-0.4%
Gross Profit	78%	156.7	+3.1%	73%	144.4	-5.4%	74%	158.8	-2.9%	74%	133.8	-0.6%	75%	593.7	-9.1	-1.5%
SG&A expenses	56%	113.5	-7.0%	61%	121.2	-4.2%	60%	127.7	+2.7%	73%	131.5	-2.5%	62%	493.9	-13.7	-2.7%
R&D expenses	20%	40.3	-6.2%	22%	43.5	-6.9%	24%	50.6	+12.0%	27%	49.6	-4.0%	23%	184.0	-2.5	-1.3%
Other expenses	36%	73.2	-7.4%	39%	77.7	-2.6%	36%	77.1	-2.6%	45%	81.9	-1.5%	39%	309.9	-11.2	-3.5%
<b>Operating Income</b>	22%	<b>43.3</b>	<b>+44.0%</b>	12%	<b>23.2</b>	<b>-11.6%</b>	15%	<b>31.1</b>	<b>-20.6%</b>	1%	<b>2.3</b>	<b>-1422.3%</b>	13%	<b>99.8</b>	<b>4.6</b>	<b>+4.8%</b>
Non-operating income		1.8			1.9			2.6			0.9			7.2	0.2	
Non-operating expenses		1.7			2.0			-0.1			3.4			7.0	0.9	
<b>Ordinary Income</b>	22%	<b>43.4</b>	<b>+34.8%</b>	12%	<b>23.1</b>	<b>-12.6%</b>	16%	<b>33.7</b>	<b>-12.9%</b>	0%	<b>-0.2</b>	-	13%	<b>100.0</b>	<b>3.8</b>	<b>+4.0%</b>
Extraordinary income		0.8			3.8			1.4			4.3			10.2	5.7	
Extraordinary losses		4.2			1.0			0.7			15.0			20.9	9.3	
Income before income taxes and minority interests	20%	40.0	+18.8%	13%	25.9	-1.6%	16%	34.4	-8.6%	-6%	-10.9	-	11%	89.3	0.2	+0.2%
Income taxes		17.7			7.5			8.5			-3.1			30.6	-23.7	
Minority interests																
<b>Net Income</b>	11%	<b>22.3</b>	<b>+122.8%</b>	9%	<b>18.3</b>	<b>+39.4%</b>	12%	<b>26.0</b>	<b>+30.0%</b>	-4%	<b>-7.8</b>	-	7%	<b>58.8</b>	<b>23.9</b>	<b>+68.6%</b>
<b>Ranbaxy Group</b>																
<b>Net sales</b>	100%	<b>54.9</b>	<b>+84.9%</b>	100%	<b>43.8</b>	<b>+20.1%</b>	100%	<b>35.5</b>	<b>-1.4%</b>	100%	<b>38.9</b>	<b>-12.6%</b>	100%	<b>173.1</b>	<b>26.4</b>	<b>+18.0%</b>
Cost of sales	35%	19.2	+12.0%	46%	20.0	-1.8%	55%	19.5	-1.7%	54%	21.0	+16.6%	46%	79.8	4.4	+5.8%
Gross Profit	65%	35.7	+184.1%	54%	23.7	+48.0%	45%	16.0	-1.1%	46%	17.9	-32.5%	54%	93.3	22.1	+31.0%
SG&A expenses	30%	16.4	+13.9%	39%	17.1	+2.9%	43%	15.4	+5.3%	43%	16.7	-13.5%	38%	65.6	0.7	+1.0%
R&D expenses	6%	3.3	+56.2%	7%	3.0	+32.0%	8%	2.8	+19.0%	7%	2.8	-19.0%	7%	12.0	1.7	+16.7%
Other expenses	24%	13.1	+6.7%	32%	14.1	-1.8%	35%	12.5	+2.6%	36%	13.9	-12.3%	31%	53.5	-1.1	-2.0%
<b>Operating Income</b>	35%	<b>19.3</b>	<b>-1171.9%</b>	15%	<b>6.6</b>	<b>-1214.7%</b>	2%	<b>0.6</b>	<b>-60.0%</b>	3%	<b>1.1</b>	<b>-83.9%</b>	16%	<b>27.7</b>	<b>21.4</b>	<b>+338.8%</b>
Non-operating income		10.0			-3.0			4.9			4.2			16.2	-5.0	
Non-operating expenses		1.1			2.7			0.1			0.1			3.9	-10.5	
<b>Ordinary Income</b>	52%	<b>28.3</b>	<b>-220.1%</b>	2%	<b>0.9</b>	<b>-95.4%</b>	16%	<b>5.5</b>	<b>+374.9%</b>	14%	<b>5.3</b>	<b>-65.1%</b>	23%	<b>40.0</b>	<b>27.0</b>	<b>+207.8%</b>
Extraordinary income		0.0			5.2			0.0			-0.1			5.1	3.8	
Extraordinary losses		0.7			0.1			1.5			6.0			8.3	8.2	
Income before income taxes and minority interests	50%	27.6	-217.5%	14%	6.0	-70.2%	11%	4.0	+249.7%	-2%	-0.8	-	21%	36.8	22.6	+158.6%
Income taxes		9.2			1.5			0.1			2.4			13.2	3.4	
Minority interests		0.1			0.1			0.1			0.1			0.3	0.1	
<b>Net Income</b>	33%	<b>18.4</b>	-	10%	<b>4.5</b>	<b>-68.3%</b>	11%	<b>3.8</b>	-	-9%	<b>-3.3</b>	-	14%	<b>23.3</b>	<b>19.1</b>	<b>+456.4%</b>
<b>Inter-segment Transactions</b>																
<b>Net sales</b>		<b>-0.1</b>			<b>-0.1</b>			<b>-0.1</b>			<b>-0.9</b>			<b>-1.2</b>		
Cost of sales		0.0			0.0			0.1			0.0			0.1		
Gross Profit		-0.1			-0.1			-0.2			-0.9			-1.3		
SG&A expenses		1.5			0.7			1.0			1.0			4.1		
R&D expenses		0.0			-0.8			-0.4			-0.4			-1.7		
Other expenses		1.5			1.5			1.4			1.4			5.8		
<b>Operating Income</b>		<b>-1.5</b>			<b>-0.7</b>			<b>-1.2</b>			<b>-1.9</b>			<b>-5.4</b>		
Non-operating income		0.0			-0.7			-0.1			0.5			-0.2		
Non-operating expenses					0.1			0.0			2.5			2.6		
<b>Ordinary Income</b>		<b>-1.5</b>			<b>-1.5</b>			<b>-1.3</b>			<b>-3.9</b>			<b>-8.2</b>		
Extraordinary income		0.0			-2.2			-0.5			0.1			-2.5		
Extraordinary losses					0.2			0.0			-5.2			-5.0		
Income before income taxes and minority interests		-1.5			-3.9			-1.7			1.4			-5.7		
Income taxes		-0.3			-0.8			-0.6			-0.2			-2.0		
Minority interests		6.4			0.7			1.1			-0.1			8.2		
<b>Net Income</b>		<b>-7.6</b>			<b>-3.8</b>			<b>-2.2</b>			<b>1.6</b>			<b>-12.0</b>		

## 4. Sales by Business Units (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Consolidated Net Sales</b>	<b>256.4</b>	<b>+12.9%</b>	<b>242.5</b>	<b>-0.4%</b>	<b>249.2</b>	<b>-2.3%</b>	<b>219.3</b>	<b>-3.2%</b>	<b>967.4</b>	<b>+1.6%</b>
<b>Japan Company (domestic sales)</b>	<b>105.3</b>	<b>+0.6%</b>	<b>103.0</b>	<b>-1.7%</b>	<b>116.8</b>	<b>-1.4%</b>	<b>91.0</b>	<b>+7.6%</b>	<b>416.0</b>	<b>+0.9%</b>
Olmotec	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Calblock	3.7	+6.5%	3.5	+0.6%	3.8	-0.6%	2.9	+1.3%	14.0	+1.9%
Loxonin	13.0	+15.9%	13.9	+11.0%	14.7	+10.0%	12.6	+27.3%	54.2	+15.3%
Cravit	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Mevalotin	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Artist	6.1	+1.8%	5.8	-1.6%	6.3	-0.9%	5.4	+8.5%	23.7	+1.6%
Omnipaque	6.4	-10.1%	6.6	-12.4%	6.5	-8.5%	5.4	-0.2%	25.0	-8.3%
Urief	2.5	+11.2%	2.5	+9.2%	2.8	+9.2%	2.3	+16.5%	10.1	+11.3%
Inavir	-	-	-	-	2.8	-	3.9	-	6.6	-
Vaccines	1.7	+36.2%	4.6	+139.8%	8.5	-1.2%	2.9	+128.3%	17.8	+35.6%
Daiichi Sankyo Espha products	-	-	-	-	2.6	-	2.0	-	4.6	-
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>9.3</b>	<b>-2.7%</b>	<b>11.7</b>	<b>-12.9%</b>	<b>13.2</b>	<b>+9.1%</b>	<b>10.6</b>	<b>+23.2%</b>	<b>44.8</b>	<b>+2.6%</b>
<b>Daiichi Sankyo, Inc. (US)</b>	<b>33.6</b>	<b>+1.7%</b>	<b>33.9</b>	<b>+1.2%</b>	<b>34.6</b>	<b>+0.6%</b>	<b>28.4</b>	<b>-11.6%</b>	<b>130.5</b>	<b>-1.9%</b>
Olmesartan	25.2	+0.6%	24.7	-2.5%	24.6	-6.9%	19.9	-19.8%	94.5	-7.1%
Benicar/Benicar HCT	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor	-	-	0.7	-	0.5	-	0.3	-	1.5	-
Welchol	7.0	+1.8%	7.4	+13.4%	7.9	+7.6%	6.3	-8.3%	28.5	+3.6%
Effient (alliance revenue)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>14.7</b>	<b>+10.4%</b>	<b>13.7</b>	<b>+1.3%</b>	<b>11.5</b>	<b>-8.5%</b>	<b>14.0</b>	<b>+10.5%</b>	<b>53.9</b>	<b>+3.5%</b>
Venofer	8.4	+5.2%	7.7	-5.0%	5.8	-27.1%	8.7	+8.4%	30.7	-4.6%
<b>Daiichi Sankyo Europe GmbH</b>	<b>14.8</b>	<b>-14.6%</b>	<b>16.6</b>	<b>-10.0%</b>	<b>18.1</b>	<b>-5.0%</b>	<b>16.9</b>	<b>-17.2%</b>	<b>66.4</b>	<b>-11.7%</b>
Olmesartan	9.6	+4.5%	11.7	+4.5%	13.4	+7.9%	11.5	-14.7%	46.2	-0.2%
Olmetec/Olmetec Plus	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT	-	-	-	-	1.0	-	0.1	-	1.1	-
<b>Asia, South and Central America (ASCA)</b>	<b>5.9</b>	<b>+12.7%</b>	<b>7.1</b>	<b>+12.8%</b>	<b>6.8</b>	<b>+3.3%</b>	<b>7.6</b>	<b>-0.4%</b>	<b>27.4</b>	<b>+6.4%</b>
Daiichi Sankyo Pharmaceutical (Beijing)	1.1	+17.8%	1.1	+3.6%	1.1	-6.3%	0.9	-2.2%	4.2	+2.9%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.4	+35.5%	1.7	+32.5%	1.6	+10.5%	1.8	+20.7%	6.6	+23.8%
Daiichi Sankyo Taiwan	0.8	-8.6%	0.8	+1.0%	0.8	+13.5%	1.0	+29.2%	3.4	+7.9%
Daiichi Sankyo Korea	1.0	+31.4%	0.9	+2.9%	1.0	+9.7%	1.1	+29.6%	4.0	+17.9%
Daiichi Sankyo (Thailand)	0.2	+35.8%	0.3	+22.8%	0.3	+53.4%	0.3	+26.9%	1.2	+33.8%
Daiichi Sankyo Brasil Farmacêutica	1.0	+36.5%	1.4	+39.5%	1.4	+6.4%	1.3	-19.9%	5.2	+9.5%
Daiichi Sankyo Venezuela	0.4	-46.7%	0.7	-18.7%	0.6	-25.1%	1.1	-32.7%	2.9	-30.5%
<b>Ranbaxy Laboratories Limited</b>	<b>54.8</b>	<b>+84.7%</b>	<b>43.7</b>	<b>+19.9%</b>	<b>35.4</b>	<b>-1.6%</b>	<b>38.0</b>	<b>-14.5%</b>	<b>171.9</b>	<b>+17.3%</b>
<b>Others</b>	<b>18.0</b>	<b>+25.6%</b>	<b>12.8</b>	<b>-25.1%</b>	<b>12.7</b>	<b>-20.2%</b>	<b>12.8</b>	<b>-20.0%</b>	<b>56.3</b>	<b>-11.1%</b>
Levofloxacin export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Effient alliance revenue (Europe)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%



**[Reference] Sales in Local Currency (FY2010)**

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
<b>Daichi Sankyo, Inc. (US)</b>	<b>365</b>	<b>+7.6%</b>	<b>394</b>	<b>+10.2%</b>	<b>422</b>	<b>+10.3%</b>	<b>342</b>	<b>-3.3%</b>	<b>1,522</b>	<b>+6.3%</b>
Olmesartan	274	+6.4%	287	+6.2%	300	+2.3%	241	-12.2%	1,102	+0.6%
Benicar/Benicar HCT	233	+2.7%	241	+1.6%	251	-0.5%	205	-15.2%	930	-2.9%
Azor	42	+33.1%	39	+16.9%	42	+4.6%	32	-1.0%	155	+12.7%
Tribenzor	-	-	7	-	6	-	4	-	17	-
Welchol	76	+7.6%	85	+23.1%	95	+17.8%	76	+0.3%	333	+12.2%
Effient (alliance revenue)	4	-	9	-	13	-	15	-	40	-
USD Mn										
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>160</b>	<b>+16.7%</b>	<b>159</b>	<b>+10.6%</b>	<b>142</b>	<b>+1.2%</b>	<b>168</b>	<b>+20.1%</b>	<b>629</b>	<b>+12.1%</b>
Venofer	92	+11.3%	90	+3.8%	72	-18.5%	104	+17.5%	358	+3.4%
EUR Mn										
<b>Daichi Sankyo Europe GmbH</b>	<b>126</b>	<b>-3.2%</b>	<b>149</b>	<b>+8.3%</b>	<b>161</b>	<b>+12.1%</b>	<b>150</b>	<b>-7.0%</b>	<b>587</b>	<b>+2.3%</b>
Olmesartan	82	+18.4%	105	+25.4%	119	+27.3%	102	-3.9%	408	+15.7%
Olmotec/Olmotec Plus	68	+8.5%	83	+12.0%	90	+16.1%	83	-7.6%	324	+6.5%
Sevikar	14	+109.5%	21	+136.0%	20	+24.9%	18	+12.8%	74	+53.6%
Sevikar HCT	-	-	-	-	9	-	1	-	10	-
INR Bn										
<b>Ranbaxy Laboratories Limited</b>	<b>28</b>	<b>+76.3%</b>	<b>21</b>	<b>+17.1%</b>	<b>19</b>	<b>+4.6%</b>	<b>21</b>	<b>-9.0%</b>	<b>89</b>	<b>+18.5%</b>

**5. Sales of Global Products (FY2010)**

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Olmesartan</b>	<b>60.2</b>	<b>+7.6%</b>	<b>61.4</b>	<b>+3.4%</b>	<b>65.7</b>	<b>+1.6%</b>	<b>54.2</b>	<b>-7.0%</b>	<b>241.5</b>	<b>+1.4%</b>
Olmotec (JPN)	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas (JPN)	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Benicar/Benicar HCT (US)	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor (US)	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor (US)	-	-	-	-	0.5	-	0.3	-	1.5	-
Olmotec/Olmotec Plus (EU)	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar (EU)	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT (EU)	-	-	-	-	1.0	-	0.1	-	1.1	-
Other subsidiaries, export, etc	2.8	+7.7%	3.9	+25.4%	3.5	-6.2%	3.8	+0.8%	13.9	+6.0%
<b>Levofloxacin</b>	<b>17.0</b>	<b>-14.3%</b>	<b>16.9</b>	<b>-28.0%</b>	<b>18.1</b>	<b>-18.3%</b>	<b>17.2</b>	<b>-21.1%</b>	<b>69.1</b>	<b>-20.7%</b>
Cravit (JPN)	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Other subsidiaries	2.1	+15.8%	2.2	+10.6%	2.1	+2.0%	2.2	+25.6%	8.7	+12.9%
<b>Pravastatin</b>	<b>11.9</b>	<b>-19.1%</b>	<b>11.8</b>	<b>-21.5%</b>	<b>11.6</b>	<b>-21.8%</b>	<b>9.6</b>	<b>-8.3%</b>	<b>44.9</b>	<b>-18.4%</b>
Mevalotin (JPN)	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Other subsidiaries, export, etc	1.7	-25.8%	1.7	-34.1%	1.6	-20.9%	1.8	-6.1%	6.8	-22.8%
<b>Prasugrel (alliance revenue)</b>	<b>0.8</b>	<b>-</b>	<b>1.0</b>	<b>-</b>	<b>1.5</b>	<b>-</b>	<b>2.0</b>	<b>-</b>	<b>5.2</b>	<b>+889.6%</b>
Effient alliance revenue (US)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Effient alliance revenue (EU)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

## Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance
<b>Japan Company (domestic sales)</b>					
Olmotec	olmesartan	antihypertensive	2004	Daiichi Sankyo	Kowa
Rezaltas	olmesartan / azelnidipine	antihypertensive	2010	Daiichi Sankyo	
Calblock	azelnidipine	antihypertensive	2003	Ube Industries	
Loxonin			1986	Daiichi Sankyo	
Loxonin Poultice			2006	Lead Chemical	
Loxonin Tape	loxoprofen	analgesic and anti-inflammatory	2008	Lead Chemical	
Loxonin Gel			2010	Daiichi Sankyo	
Cravit	levofloxacin	antibacterial	1993	Daiichi Sankyo	
Mevalotin	pravastatin	antihyperlipidemic	1989	Daiichi Sankyo	
Artist	carvedilol	antihypertensive	1993	Roche	
Omnipaque	iohexol	contrast medium	1987	GE Healthcare	
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei
Inavir	laninamivir	anti-influenza	2010	Daiichi Sankyo	
New Memary	memantine	treatment for Alzheimer's Disease	2011	Merz	
New Nexium	esomeprazole	proton pump inhibitor	2011	AstraZeneca	AstraZeneca
<b>Daiichi Sankyo, Inc. (US)</b>					
Olmesartan					
Benicar	olmesartan		2002		
Benicar HCT	olmesartan / hydrochlorothiazide		2003		
Azor	olmesartan / amlodipine	antihypertensive	2007	Daiichi Sankyo	
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010		
Welchol	colesevelam	antihyperlipidemic / type 2 diabetes	2000	Genzyme	
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly
<b>Luitpold Pharmaceuticals, Inc. (US)</b>					
Venofer	iron sucrose injection	iron deficiency anemia	2000	Vifor Pharma	Fresenius
<b>Daiichi Sankyo Europe GmbH</b>					
Olmesartan					
Olmotec	olmesartan		2002		
Olmotec Plus	olmesartan / hydrochlorothiazide		2005		
Sevikar	olmesartan / amlodipine	antihypertensive	2009	Daiichi Sankyo	Menarini Pfizer Nycomed
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010		
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly